Gene therapy in a murine model for clinical application to multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Gene Therapy

Background:

• Experimental autoimmune encephalomyelitis (EAE) is a mouse model for multiple sclerosis, characterized by autoimmune attacks on the central nervous system.
• Current EAE treatments often lack specificity and can cause significant side effects.
• Developing antigen-specific therapies to induce immune tolerance is a key goal for treating autoimmune diseases.

Purpose of the Study:

• To evaluate the efficacy of fibroblast-mediated delivery of myelin antigens for treating established EAE.
• To investigate the immunological mechanisms underlying the therapeutic effects.
• To assess the potential for clinical translation of this gene therapy approach.

Main Methods:

• Female SJL/J mice with EAE were injected with syngeneic fibroblasts engineered to secrete proteolipid protein (101-157).
• Therapy was administered at different disease stages and doses to assess efficacy and dose-dependency.
• Clinical and histological disease scores were evaluated, alongside cytokine analysis of lymphocytes from the brain and spinal cord.

Main Results:

• Fibroblast-mediated antigen delivery significantly abrogated clinical and histological signs of EAE.
• Treatment was effective even when initiated after disease relapses and protected naive mice from disease induction.
• The therapy induced an anti-inflammatory Th2 cytokine profile, suggesting a mechanism involving cytokine-induced pathways and T-cell anergy.

Conclusions:

• Fibroblast-targeted secretion of specific antigens is a potent strategy for treating autoimmune neuroinflammation like EAE.
• This antigen-specific immunotherapy induces a shift towards an anti-inflammatory immune response.
• The approach holds promise for clinical application in autoimmune diseases, with potential for using encapsulated allogeneic cells.